Zelira Therapeutics (FRA:G1G) EPS (Basic): €-0.19 (TTM As of Jun. 2025)

What is Zelira Therapeutics EPS (Basic)?

Zelira Therapeutics FRA:G1G 1 EPS (Basic) is €-0.19 as of Jun. 2025. GuruFocus rates FRA:G1G with a GF Score™ of 1/100 and a GF Value™ of €0.07. The stock has 7 warning signs investors should review.

Zelira Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Jun. 2025 was €-0.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.19.

Zelira Therapeutics's EPS (Diluted) for the six months ended in Jun. 2025 was €-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.19.

Zelira Therapeutics's EPS without NRI for the six months ended in Jun. 2025 was €-0.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2025 was -0.19.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Zelira Therapeutics (FRA:G1G) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Zelira Therapeutics EPS (Basic) Related Terms

Zelira Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics EPS (Basic) Chart

Zelira Therapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EPS (Basic)

Get a 7-Day Free Trial

-0.81

-1.03

-0.34

-1.99

-0.18

Zelira Therapeutics Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
EPS (Basic)	Get a 7-Day Free Trial															-0.13	-1.86	-0.12	-0.13	-0.06

1GF Score

Zelira Therapeutics Ltd FRA:G1G

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Zelira Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Zelira Therapeutics's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.048	-	0)	/	11.483
	=	-0.18

Zelira Therapeutics's Basic EPS for the quarter that ended in Jun. 2025 is calculated as

Basic EPS (Q: Jun. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.687	-	0)	/	11.619
	=	-0.06

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.19

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of €-0.19 mean?

Zelira Therapeutics (FRA:G1G) has a EPS (Basic) of €-0.19 as of Jun. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Zelira Therapeutics and its competitors.

Is Zelira Therapeutics' EPS (Basic) too high?

Zelira Therapeutics' current EPS (Basic) is €-0.19. Overall, Zelira Therapeutics has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.

How does Zelira Therapeutics' EPS (Basic) compare to ENSC and PPCB?

Zelira Therapeutics' EPS (Basic) of €-0.19 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current EPS (Basic) is €-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Zelira Therapeutics stock overvalued right now?

Zelira Therapeutics (FRA:G1G) has a current EPS (Basic) of €-0.19. The stock's GF Value™ is €0.07, compared to a current price of €0.30 — trading 328.6% above its estimated fair value. The current EPS (Basic) is €-0.19. Zelira Therapeutics' overall GF Score™ is 1/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Zelira Therapeutics (FRA:G1G), the current EPS (Basic) is €-0.19 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (FRA:G1G) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of €0.30 is trading 328.6% above its estimated GF Value™ of €0.07.

Key valuation signals for FRA:G1G:

EPS (Basic): €-0.19
GF Value™: €0.07 vs. price of €0.30 (328.6% above fair value)
GF Score™: 1/100 with 7 warning signs

No single metric tells the full story. See the FRA:G1G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ENSC PPCB ACUT LSBCF ITRMF REVB SXTP ALZN VIVS AZTR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ZLDAF:USA

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.

1GF Score

Get the complete analysis for FRA:G1G

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30

Price

€0.07

GF Value

View FRA:G1G Analysis

See EPS (Basic) data for all stocks →